Valbiotis' REVERSE-IT Study Gains International Recognition

The results of Valbiotis' REVERSE-IT clinical study have been published in the esteemed journal, Nature Communications. This publication signifies a crucial scientific endorsement for Totum•63, a plant-based ingredient proven to reduce cardiometabolic risks. The study, carried out in 52 centers across Europe, focused on individuals with prediabetes or early-stage type 2 diabetes.

Findings revealed significant decreases in fasting blood glucose levels within six months, alongside improvements in other cardiometabolic parameters. Totum•63, comprised of polyphenol-rich plant extracts, showed potential as a non-drug solution for managing diabetes risks.

This peer-reviewed publication follows prior presentations at major diabetes conferences, highlighting the growing scientific interest in Totum•63. The work supports the development of nutritional strategies for early diabetes intervention, reflecting Valbiotis' commitment to evidence-backed health solutions.